Already, 60 delegates representing 43 organizations have signed up for the Partnering Program. If you have signed up, you should have already received your welcome email with log-in details. You can log in at http://bhh2014.meeting-mojo.com and have a sneak preview of who will be attending and pre-schedule some meetings. Many of the speakers have signed up for partnering, so this is a great chance to set up 20-minute conversations with them further to their presentations.
Biotechnology & Human Health Symposium 2014 organizers announce a public lecture with Dr. Michael Zigmond, Professor of Neurology, University of Pittsburgh, who will present “Return to our Forebearers: How more exercise can lead to less neurodegeneration”.
The public lecture will take place on Sunday, July 13th at 7:00 p.m. at the Delta Prince Edward in Charlottetown. This event is free to the public and will offer a Q&A session. All are welcome to attend.
This presentation is a special opportunity for the public to learn about the latest knowledge in therapeutic treatments for neurodegenerative disease.
To view the public lecture poster and Dr. Zigmond’s full biography, click here.
Public Lecture Attendees: For those wishing to attend this FREE public lecture, please register here or call Jennifer Lenentine, PEI BioAlliance, 367-4407.
Symposium Registrations: For those planning to attend the full symposium running July 13-15th, please indicate your interest in attending this lecture as you register here.
Dr. Kabbani’s current projects at her eponymous lab at the Krasnow Institute for Advanced Study include various analyses of receptor interaction networks, both in brain tissue and using bioinformatics tools. Her presentation is entitled Cellular Mechanisms of Synaptic Growth and Regeneration driven by the Alpha 7 Nicotinic Receptor in the Brain. Full bio here.
Dr. Michael Zigmond is Professor of Neurology at University of Pittsburgh. Research focuses on cellular and animal models to examine Parkinson’s disease (PD), which they believe is a multi-factorial disorder. A major focus of the lab is the role of intracellular signaling cascades in determining the viability of dopamine (DA) neurones. He will speak about Protecting Dopamine Neurons with Neurotrophic Factors.
Genzyme’s Andre Turenne is Head of Strategy & Business Development responsible for Genzyme’s global partnering, licensing, and acquisition activities. Formerly, he was Vice President, Head of Rare Disease Business Development, Senior Director, Head of Renal Commercial Operations and Director, Cardiometabolic and Renal Business Development. Andre will be featured in the Investing in the CNS Sector Presentations.
Dr. Chesselet is the Charles H. Markham Professor of Neurology and distinguished professor in the Departments of Neurology and Neurobiology at UCLA. She was the Chair of the Neurobiology Department from 2002 to 2013 and is currently the Director of the Integrative Center for Neural Repair which includes the Center for the Study of Parkinson’s Disease at UCLA that she created in 1998. Read her full bio here.